Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers.
- Author:
Deming XU
1
;
Guoquan CHEN
;
Shengyi LI
;
Yongguang CAI
;
Huanwei CHEN
;
Huahai LING
;
Ziqing LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; adverse effects; therapeutic use; Digestive System Neoplasms; drug therapy; Drug Therapy, Combination; Female; Fluorouracil; administration & dosage; adverse effects; therapeutic use; Head and Neck Neoplasms; drug therapy; Humans; Leucovorin; administration & dosage; adverse effects; therapeutic use; Male; Middle Aged; Treatment Outcome
- From: Chinese Journal of Oncology 2002;24(1):93-95
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the feasibility of combined high dose leucovorin plus 5-fluorouracil infusion for head-neck and digestive tract cancers.
METHODSFifty-six patients with head-neck and digestive tract cancer were treated by combined high dose leucovorin (HD-CF) plus 5-fluorouracil (5-Fu) 48 hour continuous infusion with each patient receiving an average of 3.8 cycles (2-6 cycles). Twenty-five of these 56 patients were untreated and 31 recurrent. Their clinical stages were II 4, III 13 and IV 39.
RESULTSThe over all response rate (CR + PR) was 35.7% and the clinical beneficial response rate was 80.4%. The main side effects were peripheral phlebitis, suppression of bone marrow, oral ulcer, nausea and vomiting of grade I to II.
CONCLUSIONHigh dose leucovorin plus 5-fluorouracil 48 hour continuous infusion is useful with favorable cost/utility ratio for head-neck and digestive tract cancer patients. Further studies are warranted.
